Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Poster presentation

Adjuvant-dependent cytokine profiles in the context of a DNA prime-protein boost HIV-1 vaccine

R Buglione-Corbett*, K Pouliot, R Marty-Roix, K West, S Wang, E Lien and S Lu

  • * Corresponding author: R Buglione-Corbett

Author Affiliations

University of Massachusetts Medical School, Worcester, MA, USA

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P16  doi:10.1186/1742-4690-9-S2-P16

The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/9/S2/P16


Published:13 September 2012

© 2012 Buglione-Corbett et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Heterologous prime-boost vaccinations have emerged as a promising strategy to generate protective immunity against a variety of pathogens. Our previous clinical work has demonstrated that an HIV-1 gp120 DNA prime-protein boost vaccine, DP6-001, elicits enhanced neutralizing antibody responses as well as cell-mediated immune responses in humans. However, the roles of adjuvants remain largely unknown in the context of such combination vaccines.

Methods

In a mouse model, we studied the effects of adjuvants QS-21, Alum, and MPL, in the context of DP6-001. Both gp120-specific antibody and T cell responses were monitored by ELISA and intracellular cytokine staining (ICS), respectively. Innate cytokine profiles were determined in sera collected 6 hours post-immunization by Cytometric Bead Array (CBA) and Luminex assays.

Results

Serum anti-Env IgG titers were comparable between adjuvant groups. All immunized animals demonstrated comparable positive gp120-specific CD4+ and CD8+ T cell responses by ICS. Adjuvant profiles were largely determined by sera cytokines following protein boosting. QS-21 was distinguished by elevated IL-4, IFNγ, MIP-1β, and IL-1β. MPL was characterized by elevated G-CSF, KC, and RANTES. Both adjuvant groups demonstrated elevated IL-6. Production of these sera cytokine profiles required DNA priming.

Conclusion

Our data indicated that different adjuvants generate unique patterns of biomarkers, indicating that different mechanisms are involved in their action. Our results also provided useful guidance in the selection of an adjuvant for inclusion in future prime-boost strategies, with the goal of enhancing immunogenicity while minimizing reactogenicity.